Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Ranjbar, 2021
 
IRCT20200204046369N1
RCTmethylprednisolonedexamethasoneCOVID 19 hospitalizedsome concern
44/42 suggested
  • inconclusive 60 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 64 % decrease in mechanical ventilation with a moderate degree of certainty due to some concern in risk of bias
Metcovid, 2020
 
NCT04343729
RCTmethylprednisoloneplaceboCOVID 19 hospitalizedsome concern
209/207 inconclusive
  • inconclusive 8 % decrease in deaths,death D28 (PE) with a moderate degree of certainty due to some concern in risk of bias
RECOVERY dexamethasone, 2020
 
NCT04381936
RCTdexamethasonestandard of careCOVID 19 hospitalizedsome concern
2104/4321 conclusif
  • demonstrated 17 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 10 % increase in hospital discharge with a moderate degree of certainty due to some concern in risk of bias
  • suggested 23 % decrease in mechanical ventilation with a moderate degree of certainty due to some concern in risk of bias
in an exploratory subgroup analysis there was no benefit among patients who did not require oxygen (1.22 [0.86 to 1.75]; p=0.14)
Tang X, 2020
 
NCT04273321
RCTmethylprednisoloneplaceboCOVID 19 hospitalizedsome concern
43/43 suggested
  • inconclusive 0 % increase in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 78 % increase in viral clearance ,viral clearance (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias

COVID-19 severe or critically meta-analysis

COVID STEROID 2, 2021
 
NCT04509973
RCTDexamethasone 12mgdexamethasone 6mgCOVID-19 severe or criticallysome concern
497/485 inconclusive
    Jamaati, 2021
     
    IRCT20151227025726N1
    RCTdexamethasonestandard of careCOVID-19 severe or criticallysome concern
    25/25 suggested
    • inconclusive 19 % increase in deaths,death D28 (PE) with a moderate degree of certainty due to some concern in risk of bias
    • inconclusive 38 % increase in mechanical ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
    • suggested 3.9-fold increase in radiologic improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
    Munch (COVID-STEROID), 2021
     
    NCT04348305
    RCTHydrocortisoneplaceboCOVID-19 severe or criticallylow
    16/14 no results
      CAPE-COVID, 2020
       
      NCT02517489
      RCTHydrocortisoneplaceboCOVID-19 severe or criticallylow
      76/73 inconclusive
      • inconclusive 29 % decrease in death or ventilation (PE) with a high degree of certainty due to low risk of bias
      CODEX (Tomazini), 2020
       
      NCT04327401
      RCTdexamethasonestandard of careCOVID-19 severe or criticallysome concern
      151/148 inconclusive
        DEXA-COVID19, 2020
         
        NCT04325061
        RCTdexamethasonestandard of careCOVID-19 severe or criticallylow
        7/12 inconclusive
          Steroids-SARI, 2020
           
          NCT04244591
          RCTmethylprednisolonestandard of careCOVID-19 severe or criticallysome concern
          24/23 inconclusive
            11 studies excluded by filtering options (6 RCT / 5 OBS)

            PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
            Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).